Y. Cleary

发表

Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making

G. Meneses‐Lorente, N. Parrott, N. Frey, 2021, European Journal of Drug Metabolism and Pharmacokinetics.

Model‐Based Assessments of CYP‐Mediated Drug–Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development

N. Parrott, P. N. Morcos, K. Youdim, 2018, Clinical pharmacology and therapeutics.

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib

Markus Abt, Faye Vazvaei, Neil Parrott, 2018, Journal of clinical pharmacology.

Analysis of “On/Off” Kinetics of a CETP Inhibitor Using a Mechanistic Model of Lipoprotein Metabolism and Kinetics

C. Maugeais, Y. Cleary, J. Lu, 2015, CPT: pharmacometrics & systems pharmacology.

Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway

P. Hu, N. Parrott, O. Yin, 2015, European Journal of Clinical Pharmacology.

Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non–Michaelis-Menten P450 Kinetics on Fraction Metabolized

N. Qiu, N. Parrott, S. Fowler, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non–Michaelis-Menten P450 Kinetics on Fraction Metabolized

N. Qiu, N. Parrott, S. Fowler, 2017, The Journal of Pharmacology and Experimental Therapeutics.

A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier

T. Bergauer, O. Khwaja, K. Heinig, 2018, British journal of clinical pharmacology.

Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children

Bruno Reigner, Neil Parrott, Trevor N Johnson, 2018, British journal of clinical pharmacology.

Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective

Malcolm Rowland, Shinji Yamazaki, Jun Chen, 2018, Clinical pharmacology and therapeutics.

Addressing Today’s Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the SMN2 mRNA Splicing Modifier Risdiplam

Cordula Stillhart, A. Guenther, K. Heinig, 2021, Drug Metabolism and Disposition.

Clinical Drug–Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib

K. Bogman, M. Martin-Facklam, P. N. Morcos, 2017, Clinical pharmacology in drug development.

Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway

P. Hu, N. Parrott, O. Yin, 2015, European Journal of Clinical Pharmacology.

Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities

Stephen Fowler, Meret Martin-Facklam, Michael Gertz, 2017, Current Pharmacology Reports.

Analysis of “On/Off” Kinetics of a CETP Inhibitor Using a Mechanistic Model of Lipoprotein Metabolism and Kinetics

C. Maugeais, Y. Cleary, CI Kiu Weber, 2015, CPT: pharmacometrics & systems pharmacology.

Model‐Based Drug–Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy

L. Aarons, A. Galetin, K. Ogungbenro, 2021, Clinical pharmacology and therapeutics.

P.353FIREFISH Part 1: 16-month safety and exploratory outcomes of risdiplam (RG7916) treatment in infants with type 1 spinal muscular atrophy

E. Mercuri, L. Servais, G. Baranello, 2019, Neuromuscular Disorders.

Addressing Today ’ s Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the SMN2 mRNA Splicing Modifier Risdiplam S

Cordula Stillhart, D. Tuerck, A. Poirier, 2021 .

Supplementary Materials for: Model-based drug-drug interaction extrapolation strategy from adults to children –risdiplam in pediatric patients with spinal muscular atrophy

L. Aarons, A. Galetin, K. Ogungbenro, 2021 .

P.064 FIREFISH Part 1: 1-year results on motor function in infants with Type 1 spinal muscular atrophy (SMA) receiving risdiplam (RG7916)

E. Mercuri, L. Servais, O. Khwaja, 2019, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.